TY - JOUR
T1 - Homoharringtonine/omacetaxine mepesuccinate
T2 - The long and winding road to food and drug administration approval
AU - Kantarjian, Hagop M.
AU - O'Brien, Susan
AU - Cortes, Jorge
N1 - Funding Information:
H. Kantarjian and J. Cortes received research grants from ChemGenex.
PY - 2013/10
Y1 - 2013/10
N2 - Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.
AB - Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.
KW - CML
KW - Homoharringtonine (HHT)
KW - Omacetaxine mepesuccinate
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84884126310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884126310&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2013.03.017
DO - 10.1016/j.clml.2013.03.017
M3 - Review article
C2 - 23790799
AN - SCOPUS:84884126310
SN - 2152-2650
VL - 13
SP - 530
EP - 533
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 5
ER -
